

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Single Technology Appraisal


# Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen ID6462

### **Provisional Stakeholder List**

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
Alk-Abelló	All Wales Therapeutics and Toxicology     Centre
Patient/carer groups	Allied Health Professionals Federation
Allergy UK	Board of Community Health Councils in
Anaphylaxis UK	Wales
Asthma Relief Charity	<ul> <li>British National Formulary</li> </ul>
<ul> <li>Asthma + Lung UK</li> </ul>	Care Quality Commission
Fifth Sense	Department of Health - Northern Ireland
<ul> <li>NARA – The Breathing Charity</li> </ul>	Healthcare Improvement Scotland
<ul> <li>South Asian Health Foundation</li> </ul>	<ul> <li>Medicines and Healthcare products</li> </ul>
Specialised Healthcare Alliance	Regulatory Agency
<ul> <li>The Samter's Society</li> </ul>	National Association of Primary Care
	<ul> <li>National Pharmacy Association</li> </ul>
Healthcare professional groups	NHS Confederation
<ul> <li>Association for Respiratory</li> </ul>	<ul> <li>Scottish Medicines Consortium</li> </ul>
Technology and Physiology	Welsh Government
<ul> <li>Association of Respiratory Nurse Specialists</li> </ul>	<ul> <li>Welsh Health Specialised Services Committee</li> </ul>
British Geriatrics Society	
British Paediatric Respiratory Society	Possible comparator companies
<ul> <li>British Society for Allergy &amp; Clinical Immunology</li> </ul>	None
British Thoracic Society	Relevant research groups
ENT UK	<ul> <li>Asthma, Allergy and Inflammation</li> </ul>
National Heart and Lung Institute	Research Trust
Primary Care Respiratory Society UK	British Association for Lung Research
Royal College of General Practitioners	Cochrane Airways Group
Royal College of Nursing	<ul> <li>David Hide Asthma and Allergy</li> </ul>
Royal College of Pathologists	Research Centre
Royal College of Physicians	Genomics England
Royal Pharmaceutical Society	MRC Clinical Trials Unit
Royal Society of Medicine	National Institute for Health Research
UK Clinical Pharmacy Association	
	Associated Public Health groups
Others	Public Health Wales

Provisional stakeholder list for the evaluation of betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen ID6462 Issue date: September 2024

© National Institute for Health and Care Excellence 2024. All rights reserved. 1 of 2



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<ul><li>Department of Health and Social Care</li><li>NHS England</li></ul>	UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

## Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

#### **Consultees**

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

#### **Commentators**

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.